

# Kelly K Bree

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9351675/publications.pdf>

Version: 2024-02-01

18  
papers

129  
citations

1477746

6  
h-index

1372195

10  
g-index

19  
all docs

19  
docs citations

19  
times ranked

83  
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline Mutations in African American Men With Prostate Cancer: Incidence, Implications and Diagnostic Disparities. <i>Urology</i> , 2022, 163, 148-155.	0.5	3
2	Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre. <i>BJU International</i> , 2022, 130, 323-330.	1.3	8
3	Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. <i>BJU International</i> , 2022, 130, 604-610.	1.3	3
4	Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. <i>European Urology Oncology</i> , 2022, 5, 84-91.	2.6	24
5	Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. <i>JAMA Network Open</i> , 2022, 5, e223050.	2.8	23
6	All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. <i>Journal of Urology</i> , 2022, 208, 284-291.	0.2	7
7	Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021, 128, 568-574.	1.3	2
8	Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. <i>European Urology Oncology</i> , 2021, , .	2.6	1
9	Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response. <i>BJU International</i> , 2021, 128, 634-641.	1.3	5
10	Current Therapy and Emerging Intravesical Agents to Treat Non-muscle Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 513-529.	0.9	12
11	Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1258-1267.	0.2	7
12	What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. <i>Urology</i> , 2021, 157, 181-187.	0.5	8
13	Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. <i>World Journal of Urology</i> , 2021, 39, 4143-4149.	1.2	5
14	Germline Predisposition to Prostate Cancer in Diverse Populations. <i>Urologic Clinics of North America</i> , 2021, 48, 411-423.	0.8	6
15	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 1267.	0.2	0
16	Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2021, 206, 577-585.	0.2	14
17	Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Reply.. <i>Journal of Urology</i> , 2021, , 101097JU00000000000002307.	0.2	0
18	Should Patients With Non-muscle-invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors During BCG?. <i>BJU International</i> , 2021, , .	1.3	1